Application of Genome Editing Techniques in Immunology.
Agata O ZychMalgorzata BajorRadoslaw ZagożdżonPublished in: Archivum immunologiae et therapiae experimentalis (2018)
The idea of using the effector immune cells to specifically fight cancer has recently evolved into an exciting concept of adoptive cell therapies. Indeed, genetically engineered T cells expressing on their surface recombinant, cancer-targeted receptors have been shown to induce promising response in oncological patients. However, in addition to exogenous expression of such receptors, there is also a need for disruption of certain genes in the immune cells to achieve more potent disease-targeted actions, to produce universal chimeric antigen receptor-based therapies or to study the signaling pathways in detail. In this review, we present novel genetic engineering methods, mainly TALEN and CRISPR/Cas9 systems, that can be used for such purposes. These unique techniques may contribute to creating more successful immune therapies against cancer or prospectively other diseases as well.
Keyphrases
- crispr cas
- genome editing
- papillary thyroid
- squamous cell
- end stage renal disease
- signaling pathway
- poor prognosis
- chronic kidney disease
- cell therapy
- genome wide
- lymph node metastasis
- ejection fraction
- prostate cancer
- newly diagnosed
- cancer therapy
- regulatory t cells
- dendritic cells
- squamous cell carcinoma
- childhood cancer
- immune response
- prognostic factors
- oxidative stress
- peritoneal dialysis
- minimally invasive
- endoplasmic reticulum stress
- drug delivery